Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olatorepatide in Overweight or Obesity
NCT07431086Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of olatorepatide in obesity, sponsored by Regeneron Pharmaceuticals. Started Mar 2026; status: active, not recruiting.
02
Drugs
olatorepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07431086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431086.